KW 5805

Drug Profile

KW 5805

Latest Information Update: 26 May 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Boehringer Ingelheim Pharma KG; Kyowa Hakko
  • Class Antiulcers; Benzoxepins; Cytoprotectives; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Peptic ulcer

Most Recent Events

  • 26 May 2001 Discontinued-I for Peptic ulcer in Germany (Unknown route)
  • 26 May 2001 Discontinued-II for Peptic ulcer in Japan (Unknown route)
  • 12 Dec 1994 A study in animals has been added to the pharmacodynamics section .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top